ORCHARD PARK, N.Y., Aug. 17 /PRNewswire-FirstCall/ -- MINRAD International, Inc. today announced the appointment of Dennis Goupil, PhD, as the Company’s Senior Vice President Technical and Terence Vollrath as the Company’s Vice President Operations.
Prior to joining MINRAD, Goupil was the Chief Technical Officer and Vice President of Research and Development at Biocure, an early stage medical device company based in Norcross, GA. Earlier in his career, Goupil held various leadership positions at Boston Scientific, Datascope and Pharmacia focusing on the management of the research and development process and overseeing new business development. Goupil received a Bachelor of Science in Chemistry from Niagara University, a Masters of Science in Civil Engineering from the University of Cincinnati, and a Doctor of Philosophy in Physical Chemistry from Clarkson College of Technology.
Most recently, Vollrath was a consultant focusing on clients in the pharmaceuticals, chemicals, biotech and manufacturing industries. Prior to that, Vollrath held the Director of Operations positions at Aerojet Fine Chemicals and various management positions at Abbott Laboratories focusing on chemical manufacturing operations. Vollrath received his Bachelor of Science degree in Chemical Engineering from the University of Wisconsin and his Masters of Business Administration from Lake Forest Graduate School of Business.
In commenting on the new hires, Bill Burns, CEO of MINRAD stated; “Dennis and Terry both bring proven track records to MINRAD, which should allow for the acceleration of the Company’s goal achievement.”
Contact: Timothy Sheehan, VP - Corporate Development tsheehan@minrad.com (716) 855-1068 www.minrad.com
About the Company
MINRAD International, Inc. is an interventional pain management company with real-time image guidance, anesthesia and analgesia, and conscious sedation product lines. The real-time image guidance products facilitate minimally invasive surgery especially for pain management and have broad applications in orthopedics, neurosurgery, and interventional radiology. These devices enable medical professionals to improve the accuracy of interventional procedures and reduce radiation exposure. MINRAD International also manufactures and markets generic inhalation anesthetics for use in connection with human and veterinary surgical procedures. The company is developing a drug/drug delivery system for conscious sedation, which, similar to nitrous oxide in dental surgery, provides a patient with pain relief without loss of consciousness. Additional information can be found at the company’s website, http://www.minrad.com .
The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Factors that may cause actual results to differ materially from those expressed or implied by its forward-looking statements include, but are not limited to, Minrad International’s limited operating history and business development associated with being a growth stage company; its dependence on key personnel; its need to attract and retain technical and managerial personnel; its ability to execute its business strategy; the intense competition it faces; its ability to protect its intellectual property and proprietary technologies; its exposure to product liability claims resulting from the use of its products; general economic and capital market conditions; financial conditions of its customers and their perception of its financial condition relative to that of its competitors; as well as those risks described under the heading “Risk Factors” of MINRAD International’s Form 10-KSB, filed with the Securities and Exchange Commission on March 29, 2007. Although Minrad International, Inc. believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.
MINRAD International, Inc.
CONTACT: Timothy Sheehan, VP - Corporate Development of MINRADInternational, Inc., +1-716-855-1068, tsheehan@minrad.com
Web site: http://www.minrad.com/
